Citigroup Maintains Buy on Arcus Biosciences, Raises Price Target to $38
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Yigal Nochomovitz maintains a Buy rating on Arcus Biosciences (NYSE:RCUS) and raises the price target from $36 to $38.
June 03, 2024 | 3:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Citigroup analyst Yigal Nochomovitz maintains a Buy rating on Arcus Biosciences and raises the price target from $36 to $38.
The raised price target and maintained Buy rating from a reputable analyst at Citigroup is likely to positively impact investor sentiment and drive short-term price appreciation for Arcus Biosciences.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100